Background
==========

Management of patients with acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) is clinically challenging and costly \[[@B1]\]. In ARDS patients with refractory hypoxemia, neuromuscular blocking agents may facilitate mechanical ventilation and improve oxygenation. However, prolonged recovery of neuromuscular function and development of acute quadriplegic myopathy syndrome (AQMS) can occur \[[@B2]\]. While a variety of neuromuscular blockers have been utilized, it remains unclear which agent provides the optimal clinical benefit relative to the drug acquisition cost \[[@B3]\]. For example, using average wholesale prices, the cost of treating an ARDS patient with cisatracurium for 3.5 days is approximately \$267 more than if the patient received vecuronium. (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"})

###### 

Drug acquisition costs for 3.5 day cycle of neuromuscular blockade using average wholesale price (AWP)

                      Load (mg)   Mg infusion rate/hr   AWP vial (\$)   Vial size (mg)   Cost/mg (\$)   Load cost (\$)   Cycle infusion cost (\$)   Daily cost (\$)   **Total cost per cycle (\$)**   Total mgs   Opened vials   Total cost per cycle with open vials (\$)
  ------------------- ----------- --------------------- --------------- ---------------- -------------- ---------------- -------------------------- ----------------- ------------------------------- ----------- -------------- -------------------------------------------
  Vecuronium          7           4                     9.69            10               0.97           6.78             326                        93                **332**                         343         35             339
  Cisatracurium       14          8                     174.5           200              0.87           12.22            586                        168               **599**                         686         4              698
  Cost difference =                                                                                                                                                   **\$ 267**                                                 \$ 359

###### 

Drug acquisition costs for 3.5 day cycle of neuromuscular blockade using average selling price

                      Load (mg)   Mg infusion rate/hr   Mean sales price (\$)   Vial size (mg)   Cost/mg (\$)   Load cost (\$)   Cycle infusion cost (\$)   Daily cost (\$)   **Total cost per cycle (\$)**   Total mgs   Opened vials   Total cost per cycle with open vials (\$)
  ------------------- ----------- --------------------- ----------------------- ---------------- -------------- ---------------- -------------------------- ----------------- ------------------------------- ----------- -------------- -------------------------------------------
  Vecuronium          7           4                     3.58                    10               0.36           2.5              120                        34                **123**                         343         35             125
  Cisatracurium       14          8                     119.5                   200              0.60           8.4              402                        115               **410**                         686         4              478
  Cost difference =                                                                                                                                                           **\$ 287**                                                 \$ 353

Assessing the clinical and economic consequences of pharmacological interventions in ARDS patients is difficult. The reasons include a heterogeneous patient population, a wide range of supportive interventions, and complex causes of the patient\'s condition. For example, to conduct a clinical trial with sufficient statistical power to detect a 10% absolute decrease in the incidence of AQMS, a randomized clinical trial would have to enroll 800 patients in each of the two groups, assuming censoring due to mortality is 30%. In such situations where clinical studies are expensive and complicated to complete, computer modeling is an appropriate initial approach to yield insights.

The goal of this study was to address a hypothetical question via computer modeling: Would a reduction in intubation time of 6 hours and/or a reduction in the incidence AQMS from 25% to 21% in ARDS patients, provide enough benefit to justify an additional expenditure of \$267 \[[@B2],[@B4]\]?

Methods
=======

Overview of computer model
--------------------------

The numerator in the incremental cost-effectiveness ratio takes into consideration the additional costs that one intervention imposes over another. The denominator considers the incremental improvement in health related quality of life calculated as quality-adjusted life-years (QALY). Both costs and QALYs need to be considered together, otherwise death becomes the least costly option.

Using the results of our literature review, we simulated the rates of healing and complications associated with patients with ARDS, computed associated incremental costs, assumed a societal perspective for the analysis as recommended by an expert panel, estimated quality of life for relevant health states, and performed a sensitivity analysis to evaluate the impact of changing key variables \[[@B5]\].

### Markov model

Conventional models based on decision trees are limited in their ability to describe events that can occur multiple times in the care of a patient (e.g., ICU readmissions). A Markov model is a mathematical representation of patients in a series of health states. Such a model provides a tool to deal with multiple clinical uncertainties because the study can be repeated in successive iterations by varying parameters to address \"What if?\" questions. The use of Markov models is particular relevant in the ICU settings given the constantly changing nature of the patients\' disease conditions and treatments. This methodology has been applied successfully in studying the incidence of nosocomial infections in critically ill patients, and the mortality of ICU patients with sepsis \[[@B6],[@B7]\].

### Base case

For our study, we chose the following base case; a 55 year-old man is admitted to the ICU because of ARDS secondary to pneumonia (pneumonia sepsis is the most common etiology for ARDS and receives neuromuscular blockade for 3.5 days. These hypothetical patients were modeled to be in 1 of 6 mutually exclusive health states: ICU-intubated, ICU-extubated, hospital ward, long-term care, home, or death, over a period of 6 months. (Figure [1](#F1){ref-type="fig"})

![**Markov model for patient with ARDS receiving neuromuscular blockade**. Simulated patients were classified into 6 health states. Patient progression was divided into 3.5-day cycles over a 6-month period.](1472-6947-6-15-1){#F1}

A 3.5-day cycle time was chosen because it approximates the time of important clinical changes. Six months was chosen because it allows the model to consider the natural progression and resolution of the disease over a reasonable time frame. We also modeled a 1-month period. Choosing a longer period such as 12 or 24 months period would have been unnecessarily long.

### Net monetary benefit

The incremental cost-effectiveness ratio has poor statistical properties within the range of values relevant to this study \[[@B8]\]. If two drugs provide similar effectiveness, then trying to calculate the incremental cost-effectiveness ratio results in division by zero. Difficulties arise in how to place a monetary value on a clinical improvement. This valuation is performed by assigning a monetary value to a unit of effectiveness (Z), and multiplying it by the net number of units of effectiveness achieved. The value Z represents the maximum amount that society would be willing to pay for the incremental improvement in outcome (and therefore its maximum value). Medical interventions with a cost-effectiveness of less than \$35,000 (Z) per QALY are generally considered to represent acceptable value for money, i.e., be cost-effective. As there is no correct or well-accepted value of Z for a given clinical improvement, we tested a range of Z values from 0 to \$100,000. The net monetary benefit addresses these concerns by assigning a monetary value to the incremental benefit achieved, and subtracting from this the incremental cost of achieving this benefit \[[@B9]\].

A positive net monetary benefit implies that the cost of a new therapy is less than the value of the additional benefit achieved. A negative net monetary benefit implies that an intervention should be rejected, as its costs are higher than the value of the benefit achieved \[[@B10]\].

### Hospital costs and health related quality of life

Total hospital costs can be separated into fixed (which do not change in proportion to the number of ICU cases) and variable components. For example, from the facility\'s perspective, nursing care time may be considered a fixed cost, as staff is paid regardless of whether there is one more or one less ICU patient. However, we assumed that having a provider take care of an ARDS patient is an incremental cost to society, as is commonly done in cost-effectiveness studies, to reflect that, from society\'s point of view, there is a cost for the provider\'s time and expertise.

Using data gathered from the literature and utilizing a \"bottom up\" cost methodology, we estimated direct medical costs per day as the hypothetical patients progressed thru the various health states. We assumed that 10% of the costs assigned to any of the health states are for physicians\' professional services \[[@B11]\]. We assumed that daily costs in any of the health states are linear, meaning that the first ICU day, for example, is equally costly as subsequent ICU days.

Quality-adjusted life-years include a length of time component (e.g., one year) and a quality of life component (i.e., utility). Health utility is the numerical valuation of one\'s health-related quality of life on a linear scale from 0.00 (death) to 1.00 (perfect health). For example, one quality-adjusted life-year for an individual in perfect health (with a utility = 1.0) for one year (QALY = 1) is considered equivalent to two years in a health state with utility = 0.5. (QALY = 1). The advantage of using QALYs is that they combine number of years saved as well as the quality of life of those years.

Directly ascertaining utilities in critically ill patients is done infrequently and is methodologically difficult \[[@B12]\]. Published utilities from subgroups of ICU patients have been confirmed with the EuroQol scale and the Rosser index \[[@B13]-[@B15]\]. Patients in the EuroQol^©^EQ-5D scale are classified into one of 243 (3^5^) health states (mobility, self-care, usual activity, pain, mood) \[[@B16]\]. Each state is scored from 1 (normal) to 3 (the most impaired). For example, a mobility score of \"1\" indicates \"no problems in walking about,\" while a \"3\" is \"confined to bed.\" The scores for the five states can be assigned a utility valuation from the general public. For example, a EuroQol mobility (3), self-care (3), usual activity (3), pain (2), mood (1) signifies a utility of 0.08. In contrast, EuroQol mobility (1), self-care (1), usual activity (2), pain (1), mood (2) signifies a utility of 0.65.

In the Rosser classification of illness, assigning levels of disability and distress to each health state determine the quality of life of a patient. For example, Rosser Disability level VII with Distress level B (mild) indicates a utility of 0.8.

Since health values of seriously ill patients vary widely, we incorporated a wide range of quality of life for each health state, assuming no state was worse than death. (Table [3](#T3){ref-type="table"})

###### 

Costs and utilities used for each health state for computer modeling

  Health state     Cost per day (\$)   Range         Utility       Range   
  ---------------- ------------------- ------------- ------------- ------- ------------------------
  ICU intubated    2200                1400^24,25^   3700^26,27^   0.1     0.08--0.15
  ICU extubated    1500^28^            700^29^       2400          0.2     0.1 -- 0.3
  Hospital ward    700                 450^30,31^    1700          0.5     0.25--0.56^32^
  Long term care   350                 100^33^       925           0.65    0.45^34^-- 0.77^35,36^
  Home             0                                               0.80    0.78^37^-- 0.92^38,39^

Question asked of computer modeling
-----------------------------------

The computer modeling of the natural history of ARDS used incidences of progressing through the health states as estimated from the articles retrieved from the literature. We then asked the question, \"Would a reduction in intubation time of 6 hours and/or a reduction in the incidence AQMS from 25% to 21% in ARDS patients, provide enough benefit to justify an additional expenditure of \$267? Four scenarios were specifically considered (1) the agent reduces the incidence of myopathy from 25 to 21%, (2) the agent reduces the duration of mechanical ventilation by 6 hours, (3) both; (4) neither.

Sensitivity analyses
--------------------

The probabilistic sensitivity analysis considered uncertainties in all probabilities, utilities, and costs simultaneously. Mean values for the net monetary benefit were calculated for results of N = 10,000 Monte-Carlo simulations (\@Risk 4.0, Newfield, NY, Palisade Corporation). Triangular distributions were used for parameter values, with the mode being the base case and the 5th and 95th percentiles being the lower and upper limits of the ranges reported \[[@B17]\].

All costs are reported in year 2004 U.S. dollars. We discounted all future costs and quality-adjusted life-years at 3% per annum \[[@B18]\].

Results
=======

ARDS patients receiving a neuromuscular blocker have a high mortality, and unpredictable outcome, which results in large variability in costs per case. If a patient dies, there is no benefit to a drug that reduces ventilation time or AQMS incidence.

Computer modeling
-----------------

The estimated mean total cost for an ARDS patient receiving standard care for 6 months was \$62,238 (5% -- 95% percentiles \$42,259 -- \$83,766; median, \$61,885). Our computer model predicted that out of 100 hypothetical patients with ARDS, 39% would be expected to be dead after 6 months. (Table [4](#T4){ref-type="table"})

###### 

Fraction of patients in each health state after 1 month and 6 months

  [Health state]{.ul}       [After 1 month]{.ul}   [After 6 months]{.ul}
  ------------------------- ---------------------- -----------------------
  ICU intubated             28%                    6%
  ICU extubated             23%                    6%
  Hospital ward             9%                     4%
  Off site long term care   9%                     18%
  Home                      8%                     28%
  Dead                      23%                    39%

Results of literature review are in Tables [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}.

###### 

Randomized control trials of treatments for ARDS published after 1998

  **Author**                              **Derdak**^40^                             **Eisner**^41^                     **Gattinoni**^42^   **ARDS network**^43^       **Ely**^44^                        **Lagneau**^45^
  --------------------------------------- ------------------------------------------ ---------------------------------- ------------------- -------------------------- ---------------------------------- --------------------------------------------
  Subjects                                All comers ARDS                            Pneumonia ARDS                     All comers ARDS     All comers ARDS            ARDS network (age \<70)            Pa02/FiO2 \< 200
  Intervention                            Ventilation-controlled or high frequency   Tidal volume 12 ml/kg or 6 ml/kg   Supine vs. prone    Placebo vs. ketoconazole   Tidal volume 12 ml/kg or 6 ml/kg   Cisatracurium 0/4 twitches or 2/4 twitches
  \# of subjects                          147                                        320                                304                 234                        729                                102
  Mean age (yrs)                          49                                         51                                 58                  53                         46                                 56
  Severity of illness                     22\*\*                                     84\*\*\*                           40\*                81\*\*\*                   73\*\*\*                           41\*
  Pa02/FiO2                               113                                        133                                127                 145                                                           130
  ICU days                                                                                                                                                             19                                 
  Days on ventilator                      21                                                                                                                           10                                 
  In-hospital mortality                                                                                                                     35%                                                           45%
  \% with unassisted breathing at 1 mth                                              57%                                                    59%                                                           
  10 day mortality                                                                                                      25%, 21%                                                                          
  30 day mortality                        52%, 37%                                                                                                                     25%                                
  6 mth mortality                         59%, 47%                                   36%                                59%, 63%                                       30%                                
  Ventilator free days in first 28 days                                                                                                     10                                                            
  reintubation                                                                                                                                                         7.5%                               

###### 

Cohort studies of patients with ARDS published after 1999

  **Author**              **Estenssoro**^46^   **Luhr**^47^   **Davidson**^48^   **Arroliga**^49^   **Reynolds**^50^   **Angus**^13^   **Fialkow**^51^
  ----------------------- -------------------- -------------- ------------------ ------------------ ------------------ --------------- -----------------
  Study type              prospective          prospective    prospective        retrospective      retrospective      prospective     retrospective
  \# of subjects          235                  221            127                66                 720                200             30
  Mean age (yrs)          55                   61             39                 60                                    49              51
  Severity of illness     21\*\*               19\*\*         73\*\*\*           23\*\*                                17\*\*          18\*\*
  Pa02/FiO2               141                  131                               111                                                   
  ICU days (range)                                                               12                                    16 (0--93)      21
  Ventilator days                                                                                                                      
  Hospital days (range)                                       28(1--150)                                               26 (0--117)     44
  3 day mortality         34%                                                                                                          
  ICU mortality                                                                  47%                                                   47%
  In-hospital mortality   58%                                 43%                                   36%                                
  30 day mortality                             41%                               49%                                   30.5%           
  6 mth mortality                                                                                                      44.3%           
  1 yr mortality                                              47%                                                      44%             

\* SAPS; \*\*Apache 2; \*\*\* Apache 3

###### 

ICU studies of mechanically ventilated patients receiving neuromuscular blockers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            **Newman**^52^                                                                                                                                   **Rudis**^53^                                                                                                              **Kupfer**^54^                                                                              **Douglass**^55^                                                                                                         **Prielipp**^4^                                                                       **Segredo**^56^
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- -------------------------------------------------------------
  Study type                Prospective                                                                                                                                      Prospective                                                                                                                Prospective                                                                                 Retrospective                                                                                                            Prospective                                                                           Prospective

  Randomized                Yes                                                                                                                                              Yes                                                                                                                        No                                                                                          No                                                                                                                       Yes                                                                                   No

  Patients                  ICU                                                                                                                                              ICU                                                                                                                        VEC \> 6 hrs                                                                                Asthma                                                                                                                   ICU                                                                                   VEC\>24 hrs

  \# of subjects            61                                                                                                                                               77                                                                                                                         10                                                                                          25                                                                                                                       54                                                                                    16

  Mean age(yrs)             51                                                                                                                                               54                                                                                                                         34                                                                                          39                                                                                                                       49                                                                                    

  Apache score              18                                                                                                                                               73                                                                                                                                                                                                                                                                                                                                              27                                                                                    

  Neuromuscular blocker     CISATRA (n = 40) ATRA (n = 21)                                                                                                                   VEC (n = 35 standard Assessment; N= 42 nerve stim) 65 survivors                                                            VEC                                                                                         VEC 22 of 25 pts                                                                                                         CISTATRA (n = 28) VEC (n = 30)                                                        VEC

  Dose (mean)               CISATRA 3.1 ug/kg/min ATRA 10.4 ug/kg/min                                                                                                        VEC load 0.08 mg/kg infusion 0.08 mg/kg/hr dosing individualized                                                                                                                                                       492 mg (SD692 mg)                                                                                                        CISTATRA 2.6 mg/kg/hr VEC 0.9 mg/kg/hr twitch monitor                                 

  Duration of infusion      47 hrs                                                                                                                                           Standard assessment- 55.1 +/- 34.3 hrs Nerve stimulation 43.2 +/- 31.8                                                                                                                                                 6.6 days                                                                                                                 CISTATRA 80 +/- 7 h VEC 66 +/- 12 h.                                                  

  Recovery from block       1 hour 70% TOF for both drugs                                                                                                                    50% of control pts recovery was 3.5 hrs (95% CI 2--8) vs. 1.7 hrs (95% CI 1--2) in nerve stim patients                     7/10 pts with weakness, 3/10 muscle wasting, 2/10 difficulty weaning                                                                                                                                                 70% TOF ratio CISTATRA 68 +/- 13 min VEC 387 +/- 163 min, longer (P = 0.02)           7 of 16 pts had prolonged block (l6 hrs -- 7 days)

  Neuro- muscular Outcome   No patient showed evidence of weakness following discontinuation of either CISATRA or ATRA                                                       Median time for 50% of control pts to breathe spontaneously was 4.8 hrs (95% CI 3--9) compared with 2 hrs (95% CI 2--5)\   Pts with polyneuropathy 1352 mg in 7.2 days\                                                9/25 had weakness Patients with myopathy had significantly higher total dose of VEC (p \< 0.001)                         Prolonged recovery CISTATRA: 2 patients VEC : 13 patients P = 0.002\                  
                                                                                                                                                                             11 of 35 control pts had prolonged block (\>4 hr) 5/42 perip nerve stim pts had long block (p \< .05)\                     Without polyneuropathy 528 mg for 3.8 days (p0.04)                                                                                                                                                                   1 VEC patient significant myopathy                                                    
                                                                                                                                                                             3 survivors needed physical therapy for 35 to 137 days                                                                                                                                                                                                                                                                                                                                                                                

                            **deLemos**^57^                                                                                                                                  **Khuenl-Brady**^58^                                                                                                       **Leatherman**^59^                                                                          **Coakley**^60^                                                                                                          **Murray**^61^                                                                        **Coakley**^62^

  Study Type                Prospective                                                                                                                                      Prospective                                                                                                                Retrospective                                                                               Prospective                                                                                                              Prospective                                                                           Prospective

  Randomized                No                                                                                                                                               No                                                                                                                         No                                                                                          No                                                                                                                       Yes                                                                                   No

  Patients                  ICU                                                                                                                                              Block \> 2 days                                                                                                            Asthma                                                                                      ICU \>7 days                                                                                                             ICU                                                                                   ICU \>7 days

  \# of subjects            30                                                                                                                                               60                                                                                                                         107                                                                                         44                                                                                                                       40                                                                                    23

  Mean age (yrs)            42                                                                                                                                               36                                                                                                                                                                                                                     60                                                                                                                       52                                                                                    55

  Apache                    26                                                                                                                                                                                                                                                                                                                                                                      19                                                                                                                       27                                                                                    15.9

  Neuromusc. blocker        PANC with TOF titrate                                                                                                                            PANC (n = 30) PIPE (n = 30)                                                                                                ATRA, PANC, VEC                                                                                                                                                                                                      DOX, PANC                                                                             15 of 23 received

  Dose (mean)               Intermittent group (n = 14) 0.02 mg/kg/hr) Continuous Infusion (n = 16) .04 mg/kg/hr                                                             3 mg/h with both                                                                                                                                                                                                                                                                                                                                DOX (0.04 mg/kg) PANC (0.07 mg/kg)                                                    

  Duration Of infusion      6 days                                                                                                                                           \> 48 hrs                                                                                                                                                                                                              \> 7 days                                                                                                                2.5 days                                                                              

  Recovery from block       Median time to recover from paralysis was 3.5 hrs (1.82--5.18) in infusion group vs. 6.3 hrs (3.40--9.19) in intermittent bolus group (p =.10)                                                                                                                              Corticosteroids associated with more muscle weakness 20 of 69 versus 0 of 38 (p \< 0.001)                                                                                                                                                                                                                  

  Neuro- muscular Outcome   5 in the infusion group and 1 intermittent had persistent severe muscle weakness\                                                                None of the patients had muscle weakness                                                                                   20 weak patients were paralysed longer 3.4 +/- 2.4 versus 0.6 +/- 0.7 d (p \< 0.001)\       19 had motor & sensory findingss\                                                                                        DOX shorter recovery time after \>2 days of administration. (279.8 vs. 138.8 mins)\   10/23 had EMG, 9 of 10 had axonopathy, 8 were sensorimotor\
                            3 from each group had prolonged recovery \>12 hrs.                                                                                                                                                                                                                          18 of 20 weak pts paralysed \> 24 h.                                                        no relationship between neurophys. abnormality & APACHE II score, organ failure, sepsis, muscle relaxant, or steroids\   no cases of prolonged neuromuscular block                                             Mortality 21%
                                                                                                                                                                                                                                                                                                                                                                                                    Mortality 23%                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Assuming society would be willing to pay \$35,000 for an additional quality adjusted life (i.e., ceiling ratio), even if a drug (that cost \$267 more) did reduce AQMS from 25% to 21% and decrease intubation time by 6 hours, the net monetary benefit would only equal \$137. By running repeated iterations of the model, Figure [2](#F2){ref-type="fig"} has a scatter plot of the joint distribution of the mean incremental costs (mean decrease US \$96, SD \$5,134) and mean incremental QALYs (mean increase of 0.12, SD 0.0159) gained for bootstrap samples. For the base case, the net monetary benefit of reducing both AQMS and ventilation time would be positive for only 51% of patients.

![**The results of computer modeling**. The x- axis has the mean incremental QALYs and the y-axis has the mean incremental costs for the 10,000 Monte-Carlo simulations, each represented by a dot.](1472-6947-6-15-2){#F2}

Sensitivity analysis
--------------------

The net monetary benefit was positive for 50% of simulations with a ceiling ratio of \$1,000 versus 51% if the ceiling ratio was increased to \$100,000. The lack of sensitivity was caused by the mean changes in QALY and cost to be small relative to their standard deviations.

The variables that had the largest influence on the results, from most to least important, were probability from ICU intubated to death, probability from ICU intubated to extubated, and probability from ICU extubated to ward. The better the patients do overall, the larger the net monetary benefit of a drug that reduces AQMS and/or intubation times.

Discussion
==========

To properly allocate research money, computerized economic modeling should be first used to determine whether a pharmacoeconomic study can be expected to have a significant finding and thus be undertaken. ARDS patients receiving a neuromuscular blocker have a high mortality, and unpredictable outcome, which results in large variability in costs per case. If a patient dies, there is no benefit to any drug or intervention that reduces ventilation time or AQMS incidence. Consequently, a prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU to assess AQMS or intubation times is impractical.

Published studies comparing neuromuscular blockers in the ICU for ARDS are limited by the heterogeneity of study methods and outcomes (e.g., each study defined myopathy/weakness differently). We found that the best way to increase net monetary benefit would be for the drug to affect the key variable -- the chance of a patient dying. The benefit in spending extra money on such a drug is more likely to be important in a subset of critically ill patients identified as having prolonged intubation and a low chance of death.

Neuromuscular blockers and recovery
-----------------------------------

The optimal balance between sedation and paralysis in ARDS patients is unclear. Since the probability of having a positive net monetary benefit is only for 51% of patients, practitioners choosing neuromuscular blockers need to consider risk factors for a patient developing AQMS such as female gender, the number of days with dysfunction of two or more organs, duration of mechanical ventilation, and administration of corticosteroids. It may be that the recognition of the problem of AQMS and consequent avoidance of or decrease in dosing of neuromuscular blockers, particularly when corticosteroids are given concurrently, in the ICU has reduced the incidence of AQMS \[[@B19]\].

Assessing validity of computer modeling
---------------------------------------

The challenge is to design a useful model. Had we chosen to evaluate just the portion of care that occurs in the ICU, there would be less clinical uncertainty, because we would neglect what happened to the patient after ICU discharge. On the other hand, by including a six-month time frame, there is increasing uncertainty related to the complex course of the ARDS.

We tested the robustness of our modeling by comparing what our computer simulation predicted with published studies documenting the natural clinical progression of ARDS patients. For example, our model predicted that 28% of patients (base case being a 55 year- with pneumonia ARDS receiving neuromuscular blockade for 3.5 days) would be discharged home after 6 months, and that 18% would receive care in a long-term care facility. Both endpoints are consistent with a previous study of discharge disposition \[[@B20]\]. Our model also predicts that patients would have 15 ventilator free days, which matches well with published studies \[[@B21]\]. Thus, the scattergram obtained in Figure [2](#F2){ref-type="fig"} reflects the uncertainties about how the probabilities will change if a new drug is used to reduce delays in neuromuscular recovery.

Costing issues
--------------

Each facility may be able to negotiate individual contracts for neuromuscular blockers so the cost differences we estimated based on average wholesale price may not apply to a particular ICU.

Prolonged recovery from neuromuscular blockade may add costs due to additional sedative drugs, mechanical ventilation, and physician and nurse, ICU time. Importantly, the majority of the costs of treating patients with ARDS are spent on those who eventually die \[[@B22]\]. A detailed costing study of 193 critically ill adults found that factors such as severity of illness, gender, age, mechanical ventilation, emergency admission, and mortality were only able to explain 34% of the variation in average daily costs \[[@B23]\].

It may be that a good way to reduce time on mechanical ventilation is to have a full time intensivist rounding in the ICU 10--12 hours a day repeatedly evaluating the patient for extubation. However, in many ICUs this may not be available. A six-hour reduction in time on the ventilator may not be applicable in such settings. Although from society\'s perspective six-hours of ventilator time is important and measurable, from the hospital\'s perspective most of the cost of ICU care is a fixed cost. Even if a patient spends three hours less in the ICU, institutional costs may not be affected significantly because of the high overhead costs of hospital care. Different ICUs will have a different proportion of variable costs. In fact, nursing labor productivity is most sensitive to the number of admissions to the ICU each year and the method of compensating nurses (e.g., salary or hourly).

Conclusion
==========

The multifactorial etiology of AQMS, the highly variable clinical course of patients with ARDS as well as the disease\'s high mortality rate, makes the determination of whether selection of certain neuromuscular blockers decreases the incidence of AQMS or reduces intubation time difficult to answer. Our simulation computer model predicted the mean cost for ARDS patients receiving standard care for 6 months to be \$62,238, with an overall 6-month mortality of 39%. Although it would be important to determine if a particular neuromuscular blocker diminishes the incidence of AQMS, a prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU is impractical because of the highly variable clinical course of patients with ARDS.
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